P2RY12 and acute coronary syndrome: Notably, our enrollment concluded before the publication of the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes, which revised the recommendation on routine pretreatment with P2Y12 inhibitors in STEMI.